Phase 2 N=12 A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Evaluation of Patients With Adverse Events — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica
Necrobiosis Lipoidica
Primary: Change in Mean Necrobiosis Lipoidica (NL) Lesion Score — -2.7 score on a scale — p=0.005
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=30 Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
Diabetic Foot Infections
Primary: Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)…
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
Phase 2 N=5 Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Lipodystrophy
Primary: Change in Log 10 Fasting Triglycerides. — 0.1; -0.2 log 10 mg/dl
Phase 2 N=103 Leptin to Treat Lipodystrophy
Lipodystrophy
Primary: Percentage of Glycosylated Hemoglobin at Baseline, 6 Months, and 12 Months on Treatment With Metreleptin — 8.4; 8.1; 6.6; 7.2 percentage of glycated hemoglobin — p=<0.001
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
N/A N=45 Dyslipidemia and Diabetic Retinopathy
Diabetic Retinopathy · Dyslipidemia
Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr
N/A N=91 Intensive Insulin Treatment and Ischemic Foot Ulcer
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 4 N=105 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic Steatohepatitis
Primary: Liver Histology (Kleiner's et al Criteria, Hepatology 2005) — 7; 13; 24 Participants
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
N/A N=65 Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
Type 2 Diabetes Mellitus
Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05
Phase 2 N=12 Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
Lipedema · Dercum Disease
Primary: The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort — 0; 0; 0 Participants
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
N/A N=1,713 Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes
Type2 Diabetes
Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Phase 2 N=7 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
CIDP · Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Muscle Strength
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
N/A N=22 Immune Profile in Subjects With New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B…
Phase 4 N=17 Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Wound Appearance — 19; 19; 16.9; 14.5 units on a scale
Phase 2 N=4 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Pyoderma Gangrenosum
Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1
N/A N=32 Insulin Sensitivity in Patients With Atopic Dermatitis
Atopic Dermatitis/Eczema · Type 2 Diabetes
Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
Phase 2 N=37 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Median Progression-free Survival — 5 months
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Phase 2 N=109 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus · Autoimmune Diseases
Primary: Change in Stimulated C-peptide During a MMTT — 0.551; 0.506; 0.663; 0.425 Unitless back-transformed from log-scale — p== 0.5009